Advanced search
Publication Cover
Expert Review of Anti-infective Therapy Volume 14, 2016 - Issue 8
Submit an article Journal homepage
102
Views
11
CrossRef citations to date
0
Altmetric
Original Research

Effect of changing from first- to second-line antiretroviral therapy on renal function: a retrospective study based on data from a single health facility in Namibia

Francis KalemeeraSchool of Pharmacy, Faculty of Health Sciences, University of Namibia, Windhoek, Namibia
,
Christofina MbangoSchool of Pharmacy, Faculty of Health Sciences, University of Namibia, Windhoek, Namibia
,
Mwangana MubitaSchool of Pharmacy, Faculty of Health Sciences, University of Namibia, Windhoek, Namibia
,
Esther NaikakuSchool of Pharmacy, Faculty of Health Sciences, University of Namibia, Windhoek, Namibia
,
Razia GaidaDepartment of Pharmacy, Nelson Mandela Metropolitan University, Port Elizabeth, South Africa
&
Brian GodmanDepartment of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden;Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UKCorrespondence[email protected]
Pages 777-783 | Received 25 Jan 2016, Accepted 14 Jun 2016, Published online: 14 Jul 2016

References

  • Lawn SD, Harries AD, Wood R. Strategies to reduce early morbidity and mortality in adults receiving antiretroviral therapy in resource-limited settings. Curr Opinion HIV AIDS. 2010 Jan;5(1):18–26. doi:10.1097/COH.0b013e328333850f.
  • Fernandez-Fernandez B, Montoya-Ferrer AB, Sanz MD, et al. Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat. 2011;2011:1–11. Article ID 354908.
  • Shafi T, Choi MJ, Racussen LC, et al. Ritonavir-Induced acute kidney injury: kidney biopsy findings and review of literature. Clin Nephrol. 2011 Feb;75(01):60–64.
  • Boffito M. From concept to care: pharmacokinetic boosting of protease inhibitors. London: Physicians Research Network, Inc(R), New York City; 2004.
  • Ministry of Health and Socia Sevices. Namibia, in national guidelines for antiretroviral therapy. 4th ed. Windhoek: Ministry of Health and Social Services; 2014. p. 17.
  • Patel KK, Patel AK, Patel JK. Tenofovir-associated renal dysfunction in clinical practice: an observational cohort from western India. Indian J Sex Transm Dis. 2010 Jan-Jun;31(1):30–34.
  • Cao Y, Han Y, Xie J, et al. Impact of a tenofovira disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicentre study. BMC Infect Dis. 2013;13(1):301.
  • Sabolic I, Asif AR, Budach WE, et al. Gender differences in kidney function. Pflugers Arch. 2007;3(455):397–429.
  • Ray AS, Cihlar T, Robinson KL, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother. 2006;50(10):3297–3304. doi:10.1128/AAC00251-06.
  • Grigby IF. Tenofovir-associated bone density loss. Ther Clin Risk Manag. 2010;6:41–47.
  • Moss DM, Neary M, Owen A. The role of drug transporters in the kidney: lessons from tenofovir. Front Pharmacol. 2014;5:248.
  • Kearney BP, Mathias A, Mittan A, et al. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr. 2006;3(43):278–283.
  • Kiser JJ, Carten ML, Aquilante CL, et al. The effect of lopinavir/ritonavir on the renal clearance of tenofovir. Clin Pharmacol Ther. 2008 Feb;2(83):265–272.
  • Yombi JC, Pozniak A, Boffito M, et al. Antiretroviral and the kidneys in current clinical practice. AIDS. 2014;5(28):621–632.
  • Sorli Maria L, Ana G, Milagro M, et al. Chronic kidney disease prevalence and risk factors among HIV-infected patients. J Acquir Immune Defic Syndr. 2008;48(4):506–508.
  • Sarnak MJ, Levey AS, Shoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Circulation. J Am Heart Assoc. 2003; 108:2154–2169.
  • Fine DM, Gallant JE. Nephrotoxicity of antiretroviral agents: is the list getting longer? J Infect Dis. 2013;207:1349–1351.
  • Bygrave H, Kranzer K, Hilderbrand K, et al. Renal safety of a tenofovir-containing first line regimen: experience from an antiretroviral cohort in rural lesotho. PLoS One. 2011;6(3):e17609. doi:10.1371/journal.pone.0017609.
  • Mocroft A, Lundgren JD, Ross M, et al. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. Lancet HIV. 2015;3(1):e23–e32.
  • Weinstein JR, Anderson S. The aging kidney: physiological changes. Adv Chronic Kidney Dis. 2010;17(4):302–307. doi:10.1053/j.ackd.2010.05.002.
  • Mulenga L, Musonda P, Mwango A, et al. Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in Zambia. Clin Infect Dis. 2014;58:1473–1480.
  • Department: Health, Republic of South Africa. The South African antiretroviral treatment guidelines. Pretoria: Department of Health, South Africa; 2013. p. 11–13.
  • Gallant JE, Moore RD. Renal function with use of a tenofovir-containing initial antiretroviral regimen. Aids. 2009;Sep 24;23(15):1971–1975. doi:10.1097/QAD.0b013e32832c96e9.
  • Goicoechea M, Liu S, Best B, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis. 2008;197(1):102–108.
  • Gilead Sciences Incorporated. Tenofovir disoproxil fumarate prescribing information. Foster City (CA): Gilead Sciences, Inc.; 2013. Available from: http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/viread/viread_pi.pdf
  • Lascano ME, Poggio ED. Kidney function assessment by creatinine based estimation equations [Internet]. 2010. [cited 2016 Mar 14]. Available from: http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/nephrology/kidney-function/

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.